Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

161.35 +2.61 (+1.64%)
Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
News headline image
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Critical Insights From Charles River Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Wall Street Ends Wednesday In The Red As Risk Sentiment Remains Fragile: S&P 500 Movers At The Close ↗
U.S. markets close lower on Wednesday after bounce back on Tuesday, with small caps hit hardest. Investors assess economic outlook and Fed rate cut. 
Via Benzinga
Topics Economy Stocks
News headline image
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast ↗
Charles River Laboratories reported Q2 2024 revenue of $1.03 billion, a 3.2% decrease year-over-year, surpassing the $1.024 billion consensus. Adjusted EPS rose to $2.80 from $2.69. The company revised... 
Via Benzinga
News headline image
Demystifying Charles River: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Charles River In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 7 Takes On Charles River ↗
 
Via Benzinga
News headline image
Charles River Labs Plummets 17% On 'Bleaker' Expectations For 2024 ↗
Pharmaceutical demand hit the skids in the second quarter and isn't expected to improve this year. 
Via Investor's Business Daily
News headline image
Charles River Laboratories Announces Second-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Charles River to Perform Plasmid Manufacturing for AAVantgarde
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at William Blair and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024 ↗
CRL stock results show that Charles River beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Charles River Laboratories Announces First-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
The 7 Best Growth Stocks to Buy in May 2024 ↗
Find real bargains in this marketplace with these seven best growth stocks to buy today for your portfolio. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.